Cancer Genomics Consortium (CGC) 2026

Date: August 1, 2026 - August 5, 2026
Type: In-person
Location: North America
Areas of Interest: Oncology

SOPHiA GENETICS is at the 17th Annual Meeting of the Cancer Genomics Consortium. Find us at Booth #29 to see how the SOPHiA DDM™ Platform is helping laboratories move from fragmented workflows to AI-driven, integrated, end-to-end solutions, able to generate actionable, evidence-based insights at scale.

Discover a platform built for the complexity of cancer genomics, across solid tumors and hematologic malignancies, driven by its global community and trusted by 990+ institutions across 75 countries.

Drop by our booth for an in-depth demo of our end-to-end applications:

Booth #29 hours:

Sun Aug 2, 3:15 PM–8:00 PM
Mon Aug 3, 8:00 AM–6:30 PM
Tues Aug 4, 8:00 AM–5:30 PM
Wed Aug 5, 8:00 AM–11:15 AM

Learn more:

See MSK-IMPACT® Flex powered with SOPHiA DDM™ in action, comprehensive genomic profiling that spans DNA and RNA capture, as well as lpWGS
Explore our SOPHiA DDM™ for Blood Cancers, built to help labs future-proof their workflows from detection through MRD (minimal residual disease) monitoring
Learn how our collaboration with Memorial Sloan Kettering Cancer Center (MSK) is decentralizing world-class genomic capabilities for clinical researchers beyond flagship centers
Get a personalized demo from our oncology and genomics specialists

Don't miss: 🎤 Science Café Presentation, Lizmery Ferguson Schires | Royal Sonesta Houston Galleria

Whether you're running a high-volume solid tumor program or building out comprehensive hemato-oncology capabilities, our team can show you how SOPHiA DDM™ streamlines the entire process, from concept to implementation.

Book 15 minutes with our team now or simply stop by our booth. See you in Houston.

Book a Meeting

Name

This field is for validation purposes and should be left unchanged.

First Name(Required)

Last Name(Required)

Institution(Required)

Job Title(Required)

Area of Interest(Required)

Email(Required)

Phone

Country(Required)

Select US State(Required)

Privacy Policy(Required)

By checking this box, I declare that I have read and accepted in full SOPHiA GENETICS privacy policy. The data provided herein is used to process your request. Click here for more information relating to our privacy policy

Marketing Opt-In

I agree to receive information from SOPHiA GENETICS about products, services, events and promotions. I understand I will be able unsubscribe by using the link integrated with the communication at any time.

3rd Party Opt-In

I agree that SOPHiA GENETICS may share my webinar registration details with 3rd parties, and that I may receive marketing communications from these 3rd parties. I understand that I can withdraw my consent at any time.

This field is hidden when viewing the form

Job Title/Industry(Required)

CAPTCHA

Disclaimer notice:
The term SOPHIA used by the speaker refers to SOPHiA GENETICS and its products.
The opinions expressed during this presentation are these of the speaker and may not represent the opinions of SOPHiA GENETICS.
SOPHiA GENETICS does not provide support in the validation of custom products for clinical use.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.

SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.

All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.

SOPHiA DDM™ Overview

SOPHiA DDM™ for Genomics

SOPHiA DDM™ for Radiomics

SOPHiA DDM™ for Multimodal

Professional Services